Fig. 2: Model simulations overlaid with the TGI measured for various regimens in experimental study 1 in HBCx-9 tumour model. | British Journal of Cancer

Fig. 2: Model simulations overlaid with the TGI measured for various regimens in experimental study 1 in HBCx-9 tumour model.

From: Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs

Fig. 2

Treatment starts at Day 1, last dosing at Day 35 (dotted line). Solid line: simulation. Markers and error bars: data, mean tumour volume ± SEM. Data for each arm are shown when at least 6 out of 7 mice are still in the experiment. The arms are split across panels for clarity: vehicle and monotherapy (a), and combination (b, c). Rucaparib is given once (qd) or twice (bid) a day x35 days at the specified dose. Gartisertib is given once a day (qd, b) x35 days, or 1 week on 1 week off (1w1w, c) for 5 weeks total, at the specified dose.

Back to article page